First launch for edoxaban as eribulin also reaches the Japanese market
This article was originally published in Scrip
Daiichi Sankyo has launched the oral direct Factor Xa inhibitor Lixiana (edoxaban) in Japan, its first market worldwide, for the prevention of venous thromboembolism following major orthopaedic surgery.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.